Interview with Marco Caligiuri, Country Manager, Celgene Turkey
What were the first challenges you have faced as the new General Manager of Celgene turkey? In all humility, I have to say that even though it is always challenging…
Address: Celgene Türkiye
Büyükdere Cad. N:103
Şarlı İş Merkezi B Blok Daire:3
34394 Mecidiyeköy, İstanbul,Turkey
Tel: +90 212 354 1806
Web: http://www.celgene.com.tr/
Celgene is a global biopharmaceutical company committed to improving the lives of patients worldwide.
At Celgene, we seek to deliver truly innovative and life-changing drugs for our patients. Our mission as a company is to build a major global biopharmaceutical corporation while focusing on the discovery, the development, and the commercialization of products for the treatment of cancer and other severe, immune, inflammatory conditions.
There are more than 300 clinical trials at major medical centers using compounds from Celgene. Investigational compounds are being studied for patients with incurable hematological and solid tumor cancers, including multiple myeloma, myelodysplastic syndromes, chronic lymphocyte leukemia (CLL), non-Hodgkin’s lymphoma (NHL), myelofibrosis, small cell lung cancer and prostate cancer.
Celgene Turkey operates in Turkey since March 2008.
What were the first challenges you have faced as the new General Manager of Celgene turkey? In all humility, I have to say that even though it is always challenging…
Ufuk S. Kumrulu, general manager of Polifarma, and Vildan Kumrulu, member of the board, share how the company has strategized its internal investments in recent years and how it plans…
M. Sonay Gürgen, chairman of the board and general manager of Selçuk Ecza Deposu, Turkey’s largest pharma distributory, offers his insider take on the pharmaceutical value chain in Turkey, the…
Dr. Altan Demirdere, president of Novartis Group in Turkey discusses the long history of Novartis and Sandoz in the country, as well as the current issues between the Turkish pharmaceutical…
Maria Fernanda Prado, managing director of Janssen Turkey, elaborates on the unique dynamics at play in Turkey; an important emerging market. Prado addresses the challenges, advantages, and opportunities that exist…
Philipp Haas, chairman and CEO of DEVA, discusses the company’s export strategy and current positioning in the international pharmaceutical playing field. Haas also covers the changing dynamics of the industry…
Turgut Tokgöz, secretary general of the Pharmaceutical Manufacturers Association of Turkey (IEIS), provides his take on the state of the Turkish pharmaceutical sector, highlighting the challenges that the industry faces…
Dr Orhan Mutlu Topal, general manager at Emre Ecza Ilac, offers an insider take on the Turkish vaccine industry, the challenges on the horizon for the Turkish pharmaceutical sector, and the…
Cem Kolak, founder and managing director of BL Turkey, the only Turkish Third Party Logistics (3PL) firm 100 percent dedicated to the biopharmaceutical and life sciences sectors, leverages his pioneering…
Meri Istiroti, group coordinator of Liv Hospital Group, shares the hospital’s success story since its beginning in 2013 to becoming a leading private healthcare institution dedicated to service, quality, and…
Emin Çakmak, chairman of the Turkish Healthcare Travel Council, offers deep insights into the healthcare travel industry and how it stretches beyond the commonly used term of “medical tourism”. Çakmak…
Elif Çelik, executive vice president of the Healthcare Division of Eczacıbaşı Group, explains the rationale behind the group’s divestment of its generics arm and its new strategy to establish itself…
Ece Kaşıkçı, General Manager, Bristol-Myers Squibb (BMS) Turkey, outlines how BMS’ groundbreaking immuno-oncology therapy has proudly become the first product of its kind to be registered and reimbursed in the…
See our Cookie Privacy Policy Here
